Full course description
At the conclusion of this activity, learners will be able to:
- Describe current approach and role of risk assesment to guide intensity of lifestyle interventions and pharmacotherapy in cardiovascular prevention.
- Discuss genetic testing available and current role in CV prevention.
- Describe the conceptual framework for addressing residual CV risk with a focus on triglycerides and inflammation.
Texas A&M University College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
DESIGNATIONTexas A&M University College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Christie M. Ballantyne, MD, faculty for this educational activity has received grant support from: Abbott Diagnostic, Akcea, Amgen, Esperion, Ionis, Novartis, Regeneron, Roche Diagnostic, NIH, AHA and the ADA. Dr. Ballantyne has also served as a consultant for Abbott Diagnostics, Althera, Amarin, Amgen, Arrowheard, Astra Zeneca, Corvidia, Denka Seiken, Esperion, Genentech, Gilead, Matinas BioPharma, Inc. New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo.
The relevant financial relationships listed have been mitigated.PLANNERS DISCLOSURES